Status:
COMPLETED
Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea
Lead Sponsor:
AHS Cancer Control Alberta
Collaborating Sponsors:
Cross Cancer Institute
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Irinotecan (7-ethyl-10- {4(-1-piperidino)-1-piperidino} carbonyloxy camptothecin) is a semisynthetic camptothecin derivative introduced in the 1980's. Irinotecan is a prodrug metabolized by carboxyles...
Eligibility Criteria
Inclusion
- metastatic colorectal cancer to be treated with FOLFIAT chemo
Exclusion
- severely abnormal liver and kidney function
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00255229
Start Date
December 1 2002
End Date
January 1 2010
Last Update
February 25 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2